Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01597557 · ClinicalTrials.gov registry record · NA
Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial
A NA study, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- NA
- Development phase
- 261
- Enrollment target
NCT01597557 is a NA study that has completed, run by State University of New York at Buffalo. The registered enrollment target is 261 participants.
The verdict
NCT01597557, a NA study, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- NA
- Development phase
- 261 participants
- Enrollment target
Study Summary
The proposed study is designed to evaluate the effect of an intravenous infusion of magnesium sulfate in facilitating successful cardioversion of atrial fibrillation and in decreasing the energy threshold (in J) required for successful cardioversion of atrial fibrillation into sinus rhythm.
Interventions
- OTHER Placebo
- DRUG Magnesium Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01597557
The ClinicalTrials.gov registry entry for NCT01597557 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01597557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01597557 about?
NCT01597557 is a clinical study titled "Intravenous Magnesium Infusion in Patients Undergoing Cardioversion of Atrial Fibrillation Trial". The proposed study is designed to evaluate the effect of an intravenous infusion of magnesium sulfate in facilitating successful cardioversion of atrial fibrillation and in decreasing the energy threshold (in J) required for successful cardioversion of atrial fibrillation into sinus rhythm.
What is the current status of trial NCT01597557?
This trial is currently completed. It is a NA study. The enrollment target is 261 participants. The study started on 2012-04. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01597557?
The interventions under investigation include: Placebo (OTHER), Magnesium Sulfate (DRUG).
Who is sponsoring clinical trial NCT01597557?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.